Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
The effect of aprepitant and dexamethasone combination on paclitaxel-induced hypersensitivity reaction
T. Yamamoto1,*, M. Naito1, S. Hara1, T. Kudo2, Y. Miwa1
1 Department of Pharmacy, Osaka University Hospital, Suita, Osaka, Japan
2 Department of Frontier Science for Cancer and Chemotherapy Graduate School of Medicine Osaka University, Suita, Osaka, Japan
Eur. J. Gynaecol. Oncol. 2016, 37(6), 833–836; https://doi.org/10.12892/ejgo3362.2016
Published: 10 December 2016
Purpose of investigation: Dexamethasone (DEX) is often administered to prevent paclitaxel (PTX)-induced hypersensitivity reactions (HSR). The DEX dose is reduced when administered in combination with aprepitant (APR). However, the influence of that dose reduction on PTX-induced HSR has not been thoroughly studied. The present authors aimed to investigate the effects of the combined administration of APR and DEX on PTX-induced HSR. Materials and Methods: Fifty-one patients who received a three-week PTX regimen in combination with APR and DEX were retrospectively analysed. The authors compared the dose of DEX with the incidence of HSR and other toxicities. Results: Patients were stratified into two groups depending on the DEX dose, > 20 mg (group D, 33 patients), and < 12 mg (group reD, 26 patients). The incidence of HSR in Groups D and reD were 51.5% (17/33) and 53.8% (14/26), respectively. The frequencies of other toxicities between the groups were comparable. Conclusion: The findings suggest that although a reduction in DEX dose is possible when APR is co-administered, this does not affect the PTX-induced HSR. However, adverse effect should be closely monitored.